United States Breast Cancer Therapeutics Markets

 

Regular Price: USD 3,950

Special Price USD 2,765

30% OFF

* Required Fields

Regular Price: USD 3,950

Special Price USD 2,765

PAY BY INVOICE

Be the first to review this product

Table of Contents

United States Breast Cancer Therapeutics Markets, Executive SummaryIntroduction to the U.S. Breast Cancer Therapeutics MarketIntroduction to the U.S. Breast Cancer Therapeutics MarketObjectives and PurposeReport Structure and Market SegmentationPatient PopulationTotal Revenue ForecastsPercent of Revenues by Product TypeAnalysis by Major SegmentCompetitive AnalysisUnited States Breast Cancer Therapeutics Markets, Market Engineering Research MethodologyResearch ScopeObjectives and PurposeMarket Engineering Forecasting MethodologyOverviewStrategic Significance of the Market Engineering ForecastJudging Credibility and Accuracy of Market Engineering ForecastsForecast AssumptionsUnited States Breast Cancer Therapeutics Markets, Industry ChallengesIdentification of Challenges Facing the U.S. Breast Cancer Therapeutics IndustryIdentification of Challenges Facing the U.S. Breast Cancer Therapeutics IndustryPromulgating Benefits of Chemoprevention Provides Access to Untapped MarketImproving Therapeutic Ratio of Chemotherapy Maximizes ComplianceSteering Physicians Towards Using Aromatase Inhibitors for Adjuvant Therapy Guarantees Strong GrowthDemonstrating Improvements over Taxanes Ensures Successful Market PenetrationIdentifying Optimal Drug Synergies Improves Drug UtilizationExpansion of Market Requires Developing Drugs That Enhance Quality of Life and Survival RatesMinimizing the Impact of Generic Competition Is Key to Maintaining Market LeadershipStandardizing HER-2 Screening Fulfills Herceptin’s PotentialMarket Engineering Research for the U.S. Breast Cancer Therapeutics Market 1996-2006Market Overview and DefinitionsOverviewDisease Overview and Risk FactorsStaging of Breast CancerDrug Therapy OverviewBreast Cancer StatisticsMarket Engineering Research Measurement SystemMarket Engineering Research Measurement SystemMarket DriversMarket DriversNew Treatment Strategies for Adjuvant Therapy Stimulates Market GrowthNovel Drugs Offer Potential Growth OpportunitiesCampaigns Place Breast Cancer in the Public SpotlightMarket RestraintsMarket RestraintsGeneric Representation of Blockbuster Drugs Stifles Market Expansion Better Detection of Early Breast Cancer Restricts Revenue GrowthMarket Engineering Revenue Forecasts (1996-2006)Market Engineering Revenue Forecasts (1996-2006)Market TrendsSegment Share AnalysisCompetitive AnalysisCompetitive StructureMarket Share AnalysisMarket Share LeadersProduct ApprovalsMarket Engineering Research for the U.S. Breast Cancer Cytotoxic Market 1996-2006Market Overview and DefinitionsOverviewTreatment OverviewMarket Engineering Research Measurement SystemMarket Engineering Research Measurement SystemMarket DriversMarket DriversAcceptance of Taxanes in the Adjuvant Setting Expands Use in Breast CancerDrug Combinations Involving Ellence for the Treatment of Node-Positive Breast Cancer Is Set to Replace Older, Cheaper Combination TherapiesIntegration of Herceptin in Combination Chemotherapy Spurs Growth in the Cytotoxic MarketExpansion of Treatment Options for Anthracycline-Resistant and Paclitaxel-Resistant Tumors Offers Tremendous Growth OpportunitiesWider Acceptance of New Combination Therapies Will Enhance Market GrowthNew Formulation Drugs Will Propel Sales in the Cytotoxic MarketRecommendation by the National Cancer Institute (NCI) That Some Women with Node-Negative Breast Cancer ShouldReceive Chemotherapy Widens the Patients TreatedNovel Drugs Offer Potential Growth OpportunitiesMedicare Reimbursement of Oral Chemotherapeutic Spur Market GrowthNew Mammographic Images Creates New Market in Women with Small TumorsMarket RestraintsMarket RestraintsLoss of Market Exclusivity for Taxol Hinders Market GrowthSide Effects Limit Chemotherapy UseEffectiveness of Hormonal Therapy Precludes the Need for ChemotherapyIncrease Use of Zoladex in Premenopausal Women Threatens Chemotherapy UseNew Prognostic Indicator of Tumor Grade in Node-Negative Tumors Reduces Unnecessary ChemotherapyMarket Engineering Revenue Forecasts (1996-2006)Demand AnalysisPricing AnalysisRevenue ForecastsPricing TrendsAdjuvant and Recurrent Breast Cancer Market Share AnalysisCompetitive AnalysisCompetitive StructureMarket Share AnalysisMarket Share Winners and WhyProduct AnalysisProducts on the MarketEmerging Breast Cancer Cytotoxic TherapiesEmerging Breast Cancer Cytotoxic TherapiesEvacetBMS-217380 (DPPE)GemzarLY231514 (multitargeted antifolate)DoxilNovantroneLED (Liposomal Encapsulated Doxorubicin)LEP (Liposomal Encapsulated Paclitaxel)AptosynTargretinRFS-2000 (Rubitecan)EniluracilAnnamycinMarket Engineering Research for the U.S. Breast Cancer Hormonal Therapeutics Market 1996-2006Overview Overview DefinitionMarket Engineering Research Measurement SystemMarket Engineering Research Measurement SystemMarket DriversMarket DriversPure Anti-Estrogen Demonstrates Effectiveness over Current TherapiesAromatase Inhibitors Portrayed as Successor to Tamoxifen Invigorates Hormonal MarketDisplacement of Megestrol Acetate by Aromatase Inhibitors in Second-line Therapy Boosts Market RevenuesAromasin Increases Use of Aromatase InhibitorsApproval of Tamoxifen in a Preventative Setting Expands Market PotentialQuality of Life Compels Oncologists to Prefer Less-Aggressive Endocrine TherapyPrevention Study Offers Opportunities for Market ExpansionNew Generation SERM (Selective Estrogen Receptor Modulator) Fuels Late Stage MarketCombination Hormonal Therapy Expands Market BreadthMarket RestraintsMarket RestraintsPatent Expiration for Nolvadex (Tamoxifen) Impedes Market Growth RateMarket Dominance by AstraZeneca Deters New EntrantsEstablishment of an Installed Base of Tamoxifen Users Deter Penetration of New Therapies in the Adjuvant SettingCautious Attitudes Towards Chemoprevention of Breast Cancer for Healthy Women Hinders Market ExpansionMarket Engineering Revenue Forecasts (1996-2006)Demand AnalysisPricing AnalysisRevenuesCompetitive AnalysisCompetitive StructureCompetitive FactorsMarket Share AnalysisMarket Share LeaderProduct AnalysisProducts on the MarketEmerging Breast Cancer Hormonal TherapiesEmerging Breast Cancer Hormonal TherapiesFaslodexRaloxifeneEM-652LasofoxifeneIdoxifeneArzoxifene (LY353381)Market Engineering Research for the U.S. Breast Cancer Monoclonal Antibody Market 1996-2006Overview Overview DefinitionMarket Engineering Research Measurement SystemMarket Engineering Research Measurement SystemMarket DriversMarket DriversCombination Therapy Stimulates Herceptin UseExtended Average Duration of Herceptin Therapy Increases RevenuesIncorporation of HER-2 Screening in Diagnostic and Treatment Guidelines Allows Herceptin Revenue Potential to be ReachedMarket RestraintsMarket RestraintsHigh Cost of Herceptin Limits Treatment Period and Market PenetrationAdverse Cardiac Effects Seen in Conjunction with Doxorubicin Limits Market PotentialMarket Engineering Revenue Forecasts (1996-2006)Pricing AnalysisRevenuesCompetitive AnalysisCompetitive StructureCompetitive FactorsEmerging Breast Cancer Monoclonal Antibody TherapiesEmerging Breast Cancer Monoclonal Antibody TherapiesCetuximab (C225)United States Breast Cancer Therapeutics Markets, Market Engineering StrategyIntroductionIntroductionMarket Engineering Strategic RecommendationsMarket Engineering Strategic RecommendationsCorporate Management Intellectual PropertyMarketing DepartmentResearch and DevelopmentMarket Engineering Awards for the U.S. Breast Cancer Therapeutics MarketFrost & Sullivan's 1999 Market Engineering AwardsFrost & Sullivan's 1999 Market Engineering AwardsMarket Engineering AwardsMarket Engineering AwardsAward Category: Marketing Engineering Growth StrategyAward Category: Product Innovation Award Category: Product Line Strategy




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.